New cell injection aims to tame relapsed autoimmune nerve diseases
Disease control
Not yet recruiting
This early-stage study tests a new cell therapy called HY001N in 15 people with severe autoimmune neurological diseases that have not responded to standard treatments. The goal is to see if the treatment is safe and can help control the disease by targeting faulty immune cells. P…
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC